Hutch News

Hutch News

Stories tagged 'mini transplant'

A boy, his chicken and a bone marrow transplant

An experimental treatment — and an unconventional pet — offered both hope and healing for Andrew Adams’ rare and debilitating genetic disorder

June 23, 2017 | By Rachel Tompa / Fred Hutch News Service

It took a team of clinicians and years to get Andrew Adams to the other side of his life-threatening symptoms. Throughout it all, his beloved pet chicken Frightful kept his spirits up.

View story >


Three's a charm in a triple-drug combination for transplant patients

A drug with a storied past offers a new edge against an old foe

Dec. 4, 2016 | By Sabin Russell / Fred Hutch News Service

Discovered nearly 45 years ago in the volcanic soils of fabled Easter Island in the Pacific, a drug first thought of as an antifungal agent has found a new purpose by boosting the survival of leukemia patients after blood stem cell transplants. In a clinical trial conducted by Fred Hutchinson Cancer Research Center, the addition of a third drug, sirolimus, to a standard two-drug regimen effectively cut in half the incidence of acute graft-vs.-host disease, or GVHD, a common and dangerous complication of these lifesaving procedures.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

June 24, 2016

View story >


From building toys to developing cures

At 80, transplant scientist Dr. Rainer Storb can't stop tinkering with — and solving — medical puzzles

Dec. 21, 2015 | By Susan Keown / Fred Hutch News Service

Dr. Rainer Storb loves seeing and catching up with his former patients - men and women saved by his own research. He's 80 with big research goals still ahead.

View story >


Life with graft-vs.-host disease: When the transplant is just the beginning

How researchers are trying to combat this common, often debilitating side effect of treatment

April 21, 2015 | By Rachel Tompa / Fred Hutch News Service

Up to 70 percent of transplant recipients, such as Greg Grappone, develop acute graft-vs.-host disease, which crops up within the first few months of treatment, and 40 percent get chronic GVHD, the form that appears more than 100 days post-transplant. As the name implies, the chronic condition can last for years — or a lifetime — and its symptoms range from mildly annoying to disabling to life-threatening.

View story >


Gentler treatment effective for many with graft-vs.-host disease

A new study finds halving standard steroid dose treats most acute GVHD just as well; could limit dangerous side effects

Feb. 19, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

Up to 70 percent of transplant patients develop acute graft-vs.-host disease. Standard treatment for GVHD, the steroid prednisone, carries its own host of side effects. Fred Hutch's Dr. Marco Mielcarek led a new study testing lower doses of prednisone in patients with acute GVHD -- with promising results.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.